Regeneron Pharmaceuticals' stock recently declined from $13.41 to $11.01 following a clinical hold announcement, although it has gained 11.2% over the past year. Noteworthy developments include the FDA's approval of Dupixent for allergic fungal rhinosinusitis and acceptance of garetosmab's Biologics License Application, which may bolster future revenue streams. However, analysts express caution due to potential biosimilar competition and the impact of R&D expenditures on long-term growth, as Regeneron aims for $16.6 billion in revenue by 2028.
“REGENXBIO's common stock · declined from $13.41 to $11.01 · following the clinical hold announcement · true”
“Regeneron Pharmaceuticals, Inc. · is a · biotechnology company · headquartered in Tarrytown, New York”
“Regeneron Pharmaceuticals, Inc. · has a market cap of · around $82.6 billion”
“Regeneron Pharmaceuticals, Inc. · specializes in · discovering, developing, manufacturing, and commercializing transformative medicines”
“Regeneron Pharmaceuticals · has slipped · 4.8% · from its 52-week high of $821.11”
“Regeneron Pharmaceuticals · declined · marginally · over the past three months”
“REGN · gained · 11.2% · over the past 52 weeks”
“REGN · is up · 1.3% · on a YTD basis”
“Regeneron Pharmaceuticals' stock · has climbed · largely due to positive regulatory and pipeline developments”
“Regeneron Pharmaceuticals · has a consensus rating of · Strong Buy · from the 27 analysts covering it”
“Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) · announced on · February 24 · the U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis with a history of sino-nasal surgery”
“Management · stated that · the approval expands Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) indications in sino-nasal diseases · to now include AFRS, alongside chronic rhinosinusitis with nasal polyps”
